Tag: pubmed

Can Urol Assoc J. 2022 Jun 9. doi: 10.5489/cuaj.7781. Online ahead of print.

ABSTRACT

INTRODUCTION: Transrectal ultrasound (TRUS)-guided prostate biopsy is a common procedure performed to diagnose prostate cancer. The risk of infection complications is well-described in the literature, and strategies to avoid such complications continue to evolve over time. We performed a retrospective review of our infection complications and propose a strategy for improvement.

METHODS: We reviewed clinical outcomes from patients undergoing TRUS-guided prostate biopsy at our institution from November 2018 to November 2020. We reported the antimicrobial prophylaxis received, whether the biopsy was systematic or targeted, and we examined the rate of clinically significant infection complications and hospitalization.

RESULTS: Among 312 men who underwent TRUS-guided prostate biopsy during the study period, seven (2.2%) had an infection. Four patient groups with distinct antimicrobial regimen were identified; the largest of these patient groups received a three-day course of cefixime and a single dose of fosfomycin (59%). The proportion of patients with infection complications across these groups did not demonstrate a statistically significant difference (p=0.803). There was no significant difference in proportion of infection between systematic and targeted biopsy groups (3.0% vs. 0%, p=0.204). The proportion of patients hospitalized was 1.3%, with a mean length of stay of four days.

CONCLUSIONS: We report a rate of clinically significant infection following TRUS-guided prostate biopsy of 2.2%. Due to our referral pathway, we have an inconsistent approach to antimicrobial prophylaxis, although there was no statistically significant difference in infection rate between the groups. We propose a standardized approach that may lead to improved patient outcomes.

PMID:35704931 | DOI:10.5489/cuaj.7781

Popul Health Manag. 2022 Jun 15. doi: 10.1089/pop.2022.0062. Online ahead of print.

ABSTRACT

The purpose of this study was 2-fold: (1) to analyze the change in diabetes-related hospitalization rates of rural Latino older adult patients as compared with their White counterparts and (2) to determine what factors, including rural health clinic (RHC) participation in accountable care organizations (ACOs), are related to reduced disparities in diabetes-related hospitalization rates. Data for Latino Medicare beneficiaries who were served by RHCs over an 8-year period were analyzed. First, a difference-of-means test was conducted to determine whether there was a change in disparity from the pre-ACO period (2008-2011) to the post-ACO period (2012-2015). A statistically significant decrease in disparity over time was found (t = -7.6899, df = 115, P < 0.001.) Second, multiple regression analyses of 3 separate models were conducted to determine whether ACO participation contributed to reducing disparities in diabetes-related hospitalization rates between Latinos and Whites. The analyses indicated moderate evidence that consistent ACO participation is associated with lower health disparities (t = -1.947, P = 0.0525). However, this association is not significant after balancing covariates, and no causal relationship can be established. Latinos compose one of the fastest growing groups in rural as well as urban areas of the United States. It is critical that ACOs, with their emphasis on care coordination, health care quality, and value, monitor their provision of services to Latinos, rural, and other vulnerable populations.

PMID:35704880 | DOI:10.1089/pop.2022.0062

J Palliat Med. 2022 Jun 14. doi: 10.1089/jpm.2021.0560. Online ahead of print.

ABSTRACT

Background: Palliative care (PC) pharmacists can play an important role in optimizing medications for patients with serious illnesses by aligning patients’ goals with their treatment regimens. Objectives: The objectives of this study were to (1) quantify successful pharmacist deprescribing interventions incorporated in the hospital discharge plan and (2) describe deprescribing interventions by medication class, reason for discontinuation, and perception of patient/caregiver understanding and acceptance. Methods: This pilot study included 45 inpatient PC consultations and collected data on deprescribing interventions performed by PC clinical pharmacists in Maryland and Washington, D.C., U.S. Descriptive statistics were used to analyze outcomes. Results: Eighty-two percent of recommendations were successfully implemented during hospitalization and included in the discharge plan. Medication classes recommended for discontinuation included vitamins/supplements (20%), antidiabetics (13%), antiplatelets (10%), anticoagulants (10%), statins (10%), antihypertensives (7%), proton pump inhibitors/H2 blockers (7%), antibiotics (5%), dementia medications (1%), and antidepressants (1%). Top reasons for discontinuation included pill burden, unacceptable treatment burden, and potential harm outweighs potential benefit. Conclusions: Results of this study demonstrate PC pharmacists’ deprescribing recommendations have a high rate of successful implementation by the primary inpatient care team.

PMID:35704875 | DOI:10.1089/jpm.2021.0560

Am J Hypertens. 2022 Jun 15:hpac072. doi: 10.1093/ajh/hpac072. Online ahead of print.

ABSTRACT

BACKGROUND: Previous studies have reported that lean hypertensives have worse clinical outcomes than obese hypertensives. Other studies have shown that obesity confers pharmacological resistance to antihypertensive therapy. We explored whether the higher prescribed doses of antihypertensive medications in obese hypertensives were adequate for the attainment of similar on-treatment blood pressure (BP) compared to their leaner counterparts.

METHODS: A retrospective electronic health record review was undertaken in a de-identified database (N=851; predominately African American and female from an urban referral hypertension cohort. Median follow-up was 11.3 months (95% confidence interval (CI) (11.0, 11.5). Body mass index (BMI) kg/m2 was categorized as either below or above or equal to 30. Antihypertensive therapeutic intensity score (TIS) was the total daily antihypertensive dose/maximum United States Food and Drug Administration (USFDA) approved daily dose, summed across all hypertensive drugs. General linear models were used to estimate the statistical significance of continuous variables across BMI categories.

RESULTS: At baseline, systolic blood pressure (SBP) was similar between groups (p = 0.14), though it was 2.7 mm higher in the highest BMI group. Antihypertensive therapeutic intensity score (TIS) was greater in the highest BMI category at both baseline and at the end of follow-up (both P < 0.001). After covariate adjustment end of follow-up SBP and diastolic blood pressure (DBP) were higher in the obese compared to the non-obese group by 3.4 (0.6-6.1) /1.8 (0.1-3.53) mm Hg (p = 0.02, p = 0.04).

CONCLUSIONS: Attained on-treatment BP is higher in obese than non-obese hypertensives despite greater prescription of antihypertensive medications. Whether even more prescription of medications or other interventions will equalize BP responses relative to non-obese hypertensives merits further study.

PMID:35704857 | DOI:10.1093/ajh/hpac072

Acta Anaesthesiol Scand. 2022 Jun 15. doi: 10.1111/aas.14105. Online ahead of print.

ABSTRACT

BACKGROUND: Tracheostomies are commonly utilized in ICU patients due to prolonged mechanical ventilation, upper airway obstruction or surgery in the face/neck region. However, practices regarding timing of placement and utilization vary. This study provides a nationwide overview of tracheostomy utilization and outcomes in the ICU over a 14-year period.

METHODS: A retrospective study including all patients that received a tracheostomy during their ICU stay in Iceland between 2007-2020. Data was retrieved from hospital charts on admission cause, comorbidities, indication for tracheostomy insertion, duration of mechanical ventilation before and after tracheostomy placement, extubation attempts, complications, length of ICU and hospital stay and survival. Descriptive statistics were provided, and survival analysis was performed using Cox regression.

RESULTS: A total of 336 patients (median age 64 years, 33% females) received a tracheostomy during the study period. The most common indication for tracheostomy insertion was respiratory failure, followed by neurological disorders. The median duration of mechanical ventilation prior to tracheostomy insertion was nine days and at least one extubation had been attempted in 35% of the cases. Percutaneous tracheostomies were 32%. The overall rate of complications was 25% and the most common short-term complication was bleeding (5%). In-hospital mortality was 33%, and one-and five-year mortality rate was 40% and 60%, respectively.

CONCLUSIONS: We describe a whole-nation practice of tracheostomies. A notable finding is the relatively uncommon attempts of extubation prior to tracheostomy. Future work should focus on standardization in assessing the need for tracheostomy, including various patient characteristics and the role of extubation attempts prior to tracheostomy placement.

PMID:35704855 | DOI:10.1111/aas.14105

Am Fam Physician. 2022 Jun 1;105(6):577-579.

NO ABSTRACT

PMID:35704805

Hum Vaccin Immunother. 2022 Jun 15:1-10. doi: 10.1080/21645515.2022.2066424. Online ahead of print.

ABSTRACT

Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.

PMID:35704772 | DOI:10.1080/21645515.2022.2066424

Clin Lab. 2022 Jun 1;68(6). doi: 10.7754/Clin.Lab.2021.210821.

ABSTRACT

BACKGROUND: Leukemia stem cells (LSCs) have been demonstrated to be more therapy-resistant than leukemic blast cells reflecting measurable residual disease (MRD). CD34+CD38- cell frequency is an independent factor for relapse prediction and could therefore be used in the future to improve MRD assessment in acute myeloid leukemia (AML). This protocol is designed to enable accurate and reproducible immunophenotypic detection of measurable residual stem cell disease necessary for proper therapeutic decision and report their prognostic value in AML patients.

METHODS: Fifty-four Novo AML adult patients diagnosed in the onco-hematology service of the “20 August 1953” Hospital in Casablanca. We analyzed phenotype and frequency of CD45dim CD34+CD38- cells in bone marrow samples from patients with AML and non-myeloid malignancies using six-color flow cytometry and a simple one-tube essay.

RESULTS: For evaluation of leukemic stem cells, our gate strategy was based on the selection of CD34+CD38 – stem cells and leukemia associated immunophenotype approach. Positivity of CD123 or/and aberrant expression of primitive markers CD117 and HLA DR on stem cells discriminate leukemia stem cells from normal hematopoietic stem cells. We reported a statistically significant difference between expressions of primitive markers (CD117 and HLA DR) on leukemic stem cells. In addition, the frequency of LSCs after complete remission in post-induction was persistent in 50% of AML patients.

CONCLUSIONS: Overall, we show that CD34+CD38-CD123+ as a basic phenotype, with aberrant phenotype detection of HLA DR and CD117 markers on stem cells, contributes to detecting LSCs which indicates the poor prognosis.

PMID:35704721 | DOI:10.7754/Clin.Lab.2021.210821

Clin Lab. 2022 Jun 1;68(6). doi: 10.7754/Clin.Lab.2021.210853.

ABSTRACT

BACKGROUND: Nowadays, novel antimicrobial strategies are being developed which focus on debilitating, rather than killing the microorganisms. In this regard, anti-biofilm therapy is one of the important ways to combat bacterial infections. Therefore, the aim of the current study was to evaluate the anti-biofilm activity of Carvacrol against E. faecalis by means of its effects on biofilm formation as well as on the gene expression levels of the two biofilm related genes, Epa and Esp.

METHODS: A total of 40 clinical strains of E. faecalis were collected from three hospitals in Tehran, Iran during 2020. These isolates were confirmed by biochemical and genotypic methods. Antibacterial and anti-biofilm activity of Carvacrol essence were determined according the standard protocol. Finally, expression level of the biofilm related genes (Epa and Esp) were evaluated before and after the treatment with Carvacrol.

RESULTS: A total of 14 isolates were considered as strong biofilm producers and were used for analysis. Carvacrol essence showed the best antibacterial activity at 2,500 μg/mL concentration against all the isolates, the biofilm formation capacity was decreased by Carvacrol essence, and it was statistically significant (p < 0.05). Expression levels of the Esp gene were decreased in 5 isolates while increased in 3 isolates following the Carvacrol treatment. Ex-pression levels of the EpaI gene was significantly decreased (p < 0.05) in 4 isolates following the Carvacrol treatment.

CONCLUSIONS: In conclusion, the results presented in this study suggest that carvacrol extract exhibits significant antimicrobial and anti-biofilm properties against E. faecalis, even against vancomycin resistant isolates.

PMID:35704732 | DOI:10.7754/Clin.Lab.2021.210853

J Clin Psychiatry. 2022 Jun 13;83(4):21m14055. doi: 10.4088/JCP.21m14055.

ABSTRACT

Objective: To examine the incidence and predictors of suicide attempts and deaths in the year after psychiatric hospitalization.

Methods: A population-based dataset was used to develop a cohort of individuals 18 years or older admitted with a mental disorder (defined by ICD-10 codes) from 2005 to 2016 (n = 26,975) in Manitoba, Canada. Using Cox regression, hazard ratios were calculated for each covariate among those who attempted and died by suicide in the year following hospitalization, while adjusting for confounders.

Results: In the year following hospitalization for a mental disorder, 0.7% of the individuals died by suicide and 3.5% attempted suicide. Statistically significant risk factors for suicide in the year after discharge from psychiatric hospitalization included male sex (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.10-1.97) and urban location (HR, 1.37; 95% CI, 1.02-1.85) and for attempting suicide included female sex (HR, 0.63; 95% CI, 0.55-0.72), living rurally (HR, 0.66; 95% CI, 0.58-0.75), a previous mental disorder (HR, 1.63; 95% CI, 1.38-1.92), justice involvement (HR, 1.48; 95% CI, 1.28-1.70), and being on income assistance (HR, 1.17; 95% CI, 1.01-1.35) (P < .05 for all). Age (HR, 0.99; 95% CI, 0.99-0.99) (P < .05) was associated with a reduced rate of suicide attempts.

Conclusions: Further research into interventions to address the identified risk factors for suicide in the recently discharged population is critical to improve management.

PMID:35704710 | DOI:10.4088/JCP.21m14055